diabetic retinopathy
Conditions
Interventions
Test Group 1:vitrectomy with saline tamponade and subretinal anti-VEGF injection
Test Group 2:vitrectomy with saline tamponade and intravitreous anti-VEGF injection
Test Group 3:vitrectomy with silicone oil tamponade and intravitreous anti-VEGF injection
Test Group 4:vitrectomy with gas tamponade and intravitreous anti-VEGF injection
Blank Group:intravitreous anti-VEGF injection
Sponsors
Shanghai Jiaotong University Affiliated Ninth People's Hospital
Eligibility
Sex/Gender
All
Age
30 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1. aged 30 to 90 years patient male or female ; 2. subjects were not treated with anti-VEGF drugs; 3. subjects with diabetic retinopathy; 4. indicated for vitrectomy (unabsorbed or recrudescent vitreous hemorrhage, retinal detachment); 5. patients are voluntarily involved in this clinical trial and signed informed consent; 6. abide by follow-up visit according to the plan schedule;
Exclusion criteria
Exclusion criteria: 1. researchers consider who are not eligible for inclusion; 2. severe systemic diseases that may affect the results (heart failure, respiratory failure neuropathy, mental disorders, hematological disorders, immune diseaseInfectious diseases, malignant tumors and organ transplantation); 3. vitrectomy for other reasons except diabetic retinopathy; 4. history of orbital surgery; orbital deformity, trauma patients; uveitis eye, anterior chamber inflammation, keratitis, corneal degeneration.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| concentration of anti-VEGF fusion protein; | — |
Countries
China
Contacts
Public ContactZhaoyang Wang
Shanghai Jiaotong University Affiliated Ninth People's Hospital
Outcome results
None listed